Intel Group announced that Huachen Investment, the information disclosure agent, plans to transfer its 122,277,151 shares of the company to Zhejiang Pharmaceutical Group free of charge, so that Zhejiang Pharmaceutical Group can directly hold shares in listed companies. This equity change is a free transfer of state-owned equity and does not involve payment of funds. After this change in equity, Huachen Investment will no longer hold the company's shares, and Zhejiang Pharmaceutical Group will hold 23.42% of the company's shares. The controlling shareholder of the company was changed from Zhejiang Guomao to Zhejiang Pharmaceutical Group, and the actual controller is still the Zhejiang Provincial State-owned Assets Administration Commission. The purpose of this transfer is to implement Zhejiang Guomao's “pharmaceutical expansion” strategy and promote Zhejiang Pharmaceutical Group to become the main enterprise and main investment platform in the pharmaceutical industry chain in Zhejiang Province.

Intel Group announced that Huachen Investment, the information disclosure agent, plans to transfer its 122,277,151 shares of the company to Zhejiang Pharmaceutical Group free of charge, so that Zhejiang Pharmaceutical Group can directly hold shares in listed companies. This equity change is a free transfer of state-owned equity and does not involve payment of funds. After this change in equity, Huachen Investment will no longer hold the company's shares, and Zhejiang Pharmaceutical Group will hold 23.42% of the company's shares. The controlling shareholder of the company was changed from Zhejiang Guomao to Zhejiang Pharmaceutical Group, and the actual controller is still the Zhejiang Provincial State-owned Assets Administration Commission. The purpose of this transfer is to implement Zhejiang Guomao's “pharmaceutical expansion” strategy and promote Zhejiang Pharmaceutical Group to become the main enterprise and main investment platform in the pharmaceutical industry chain in Zhejiang Province.